Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Non-randomized, Uncontrolled, Open-label Phase I/II Study to Observe the Safety and Preliminary Efficacy of Catumaxomab in Patients With Non-Muscle-Invasive Bladder Cancer Who Have Failed or Are Intolerant to BCG Vaccine

NCT04799847 is registered in ClinicalTrials.gov with LintonPharm Co.,Ltd. as lead sponsor.

NCT NCT04799847
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04799847 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Non-randomized, Uncontrolled, Open-label Phase I/II Study to Observe the Safety and Preliminary Efficacy of Catumaxomab in Patients With Non-Muscle-Invasive Bladder Cancer Who Have Failed or Are Intolerant to BCG Vaccine
Lead sponsor
LintonPharm Co.,Ltd.
Phase
Phase 1/2
Overall status
Unknown status
Start date
November 23, 2021
Completion date
November 30, 2024
Enrollment
161 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer